Mizuho Reiterates Buy on BioXcel Therapeutics, Maintains $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on BioXcel Therapeutics (NASDAQ:BTAI) and maintained a $40 price target.
June 30, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst has reiterated a 'Buy' rating on BioXcel Therapeutics and maintained a $40 price target.
The reiteration of a 'Buy' rating by a Mizuho analyst and the maintenance of a $40 price target indicates a positive outlook for BioXcel Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100